Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanoma-Reference-Cited by-同舟云学术

Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanoma

Published:1991-09 Issue:5 Volume:32 Page:315-324
ISSN:0340-7004
Container-title:Cancer Immunology Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Cohen Max H.,Elin Ronald J.,Cohen Barry J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/BF01789050.pdf

Reference41 articles.

1. Briggs PC, Heckler F (1988) Axillary lymphadenopathy: complication of BCG immunotherapy for melanoma. Plast Reconstr Surg 81: 952–953

2. Clark WH, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanoma of the skin. Cancer Res 29: 705–726

3. Clark WH, Ainsworth AM, Bernardino EA, Yang CH, Mihm MC (1975) The developmental biology of primary human malignant melanomas. Semin Oncol 2: 83–103

4. Caridis DT, Reinhold RB, Woodruff PWH, Fine J (1972) Endotoxaemia in man. Lancet 1: 1381–1386

5. Cohen SG, Benaceraf B, McClusky RT, Ovary Z (1967) Effect of anticoagulants on delayed hypersensitivity reactions. J Immunol 98: 351

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG;Frontiers in Oncology;2023-04-27

2. In-transit metastatic cutaneous melanoma: current management and future directions;Clinical & Experimental Metastasis;2021-05-17

3. Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma;Cancers;2020-05-22

4. Clinical and molecular insights into BCG immunotherapy for melanoma;Journal of Internal Medicine;2020-03-04

5. Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants;Cancer Regional Therapy;2019-12-11